UniDoc Announces LIFE Offering

Rhea-AI Summary

UniDoc Health Corp (CSE:UDOC) has announced a non-brokered private placement LIFE offering to raise up to $500,000 through the issuance of up to 2,000,000 units at $0.25 per unit. Each unit comprises one common share and one-half of a transferrable warrant, with each full warrant allowing the purchase of an additional common share at $0.35 for 24 months after closing.

The proceeds will support inventory, marketing and investor relations services, working capital, and general corporate purposes. The offering, expected to close around April 11, 2025, will be conducted under the listed issuer financing exemption in British Columbia, with securities issued to Canadian residents having no resale restrictions.

Positive

• No resale restrictions for Canadian investors, improving liquidity potential
• Warrant structure provides additional upside potential at $0.35 per share

Negative

• Dilutive impact on existing shareholders through issuance of up to 2,000,000 new units
• Offering price of $0.25 per unit may represent a discount to market price

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / April 4, 2025 / UniDoc Health Corp. (CSE:UDOC) ("UniDoc" or the "Company") is pleased to announce a non-brokered private placement LIFE offering (the "Offering") for total gross proceeds of up to $500,000, consisting of up to 2,000,000 units of the Company (each, a "Unit") at a price of $0.25 per Unit.

Each Unit will consist of one common share in the capital of the Company and one-half of one transferrable common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire an additional common share at a price of $0.35 for a period of 24 months following the closing of the Offering.

The Company plans to use the proceeds from the Offering for inventory, marketing and investor relations services, working capital, and general corporate purposes.

The Units will be offered by way of the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106") in the province of British Columbia. Pursuant to NI 45-106, the securities forming part of the Units issued to Canadian resident subscribers under the Offering will not be subject to resale restrictions.

There is an offering document related to this Offering that can be accessed under the Company's profile at www.sedarplus.com and at the Company's website www.unidoctor.com. Prospective investors should read this offering document before making an investment decision.

The Offering is expected to close on or about April 11, 2025, or such other date that is within 45 days from April 4, 2025, as the Company may agree. The Offering remains subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including the approval of the CSE.

On Behalf of the Board of Directors,

~Antonio Baldassarre~

Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.

About UniDoc Health Corp. (CSE:UDOC)

UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician's office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company's belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.comand signup to receive the latest information with updates on our activities, events and progress.

For further information, please contact:

UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com

Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com

Media Inquiries media@unidoctor.com

Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to: the Offering, completion of the Offering, the expected closing date of the Offering, and the use of proceeds of the Offering. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "anticipates", "anticipated" "expected" "intends" "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are from those expressed or implied by such forward-looking statements or forward-looking information subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different, including receipt of all necessary regulatory approvals. Although management of the Company have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: UniDoc Health Corp.

View the original press release on ACCESS Newswire

FAQ

What are the terms of UniDoc Health Corp's (UDOCF) LIFE offering announced in April 2025?

The offering consists of up to 2,000,000 units at $0.25 per unit, with each unit including one common share and half a warrant. Each full warrant allows purchase of one share at $0.35 for 24 months.

How much capital is UDOCF aiming to raise through its April 2025 private placement?

UniDoc Health Corp is aiming to raise total gross proceeds of up to $500,000 through this private placement offering.

What will UniDoc Health (UDOCF) use the proceeds from its 2025 LIFE offering for?

The proceeds will be used for inventory, marketing and investor relations services, working capital, and general corporate purposes.

When is the expected closing date for UDOCF's 2025 private placement offering?

The offering is expected to close on or about April 11, 2025, or within 45 days from April 4, 2025.